Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Returns
Return on equity-28.3%-0.1pp-28.2%-4.8pp-23.4%+6.0pp-29.4%
Return on assets-26.8%+0.1pp-26.9%-4.4pp-22.6%+5.4pp-28%
Return on invested capital-38.2%-2.1pp-36.1%+3.4pp-39.5%+5.8pp-45.3%
Liquidity
Current ratio27.1×+0.9×26.2×-10.2×36.4×+13.6×22.7×-8.3×31×-4.3×
Quick ratio27.1×+0.9×26.2×-10.2×36.4×+13.6×22.7×-8.3×31×-4.3×
Cash ratio4.4×+1.6×2.8×-14.8×17.6×+12.9×4.6×-1.5×6.1×-0.3×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×0.0×
Debt-to-assets0.0×0.0×0.0×0.0×0.0×
Per Share
Book value per share$9.98-19.8%$12.45-7.7%$13.49+81.4%$7.43-8.3%$8.11-45.0%
Valuation
Market capitalization$1.5B+3.4%$1.45B+5.6%$1.37B+203%$451.84M+23.4%$366.06M-43.6%
Enterprise value$1.43B+1.7%$1.4B+24.3%$1.13B+177%$408.64M+29.2%$316.3M-46.7%
Price / book3.2×+0.2×+0.3×2.7×+1.0×1.7×+0.4×1.3×-0.8×
Free cash flow yield-5.4%+0.7pp-6.1%-0.4pp-5.7%+11.3pp-17%+1.9pp-18.9%-8.5pp
Earnings yield-7.2%+0.5pp-7.7%-0.6pp-7.1%+12.4pp-19.5%+2.2pp-21.8%-9.7pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Rapport Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Rapport Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.